iTeos Therapeutics, Inc. (ITOS) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The daily price action for iTeos Therapeutics (ITOS), which operates in the field of cancer immunotherapy, currently stands at . A lack of profitable products leaves the company dependent on previous partner tranches. Serious threats exist regarding potential late-stage trial failures and a rapid cash burn rate. Business success relies on the effectiveness of joint projects with industry behemoths and the competitiveness of new treatment methods.
iteostherapeutics.com - analytical breakdowns and key metrics (ITOS)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity iTeos Therapeutics|ITOS - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital iTeos Therapeutics, Inc.|ITOS - Company Cumulative Debt|Debts to Book Capitalization iTeos Pharma|ITOS - Long-Term Debt Volume|Company Current Liabilities iTeos Therapeutics|Quick Ratio iteostherapeutics.com
- business earnings and investment ratios data:
ITOS - Company Net Income|Expected Profit iTeos Therapeutics|ITOS - Market Cap to Earnings|Future Price to Earnings iTeos Therapeutics|ITOS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio iTeos Pharma|ITOS - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months iTeos Therapeutics|ITOS - Earnings per share for the last four quarters|Quarterly EPS earnings growth iteostherapeutics.com|ITOS - Earnings per share increase in current year|Earnings growth forecast for next year iTeos Therapeutics
Initial company analysis:iTeos ITOS
The asset quality assessment methodology requires comparing the enterprise value with its operating profit before depreciation and interest. By analyzing the EV/EBITDA multiple of iTeos Therapeutics (ITOS) over time, an investor determines the real value of the business, stripped of the impact of debt load and tax effects. For iTeos Therapeutics (ITOS), this indicator confirms capital stability supported by a strategic partnership with GSK.
Analysis of competing companies
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dianthus Corp DNTH|PHVS (Pharvaris N.V.) - Enterprise Value to EBITDA Ratio|ABCL: Enterprise Value to Operating Income Before Depreciation Ratio|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Company Value to EBITDA Precigen Inc PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|NKTR - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|Total Company Value to Operating Income Before Depreciation Ratio zenasbio.com (ZBIO)|IMNM: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GOSS (Gossamer Bio Inc)|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|SEPN: Enterprise Value to Operating Income Before Depreciation Ratio|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|SVRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple RIGL|ANAB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|Business Value to Operating Income Before Depreciation ENGN|RAPT Therapeutics - EV/EBITDA Multiple|JBIO - EV/EBITDA Multiple|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KYTX (Kyverna Therapeutics Inc.)|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Company Value to EBITDA Cabaletta Bio Inc CABA|Enterprise Value to EBITDA Ratio VTYX (Ventyx Biosciences)|EV/EBITDA Multiple theratech.com (THTX)|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ELDN (Eledon Pharmaceuticals Inc.)|Agenus Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Climb Bio, Inc CLYM|ZURA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio atyrpharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adagene Inc|Ikena Oncology, Inc. (IMA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple STTK|Total Company Value to Operating Income Before Depreciation Ratio equilliumbio.com|Connect Biopharma Holdings Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio IMUX (Immunic Therapeutics)|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA InflaRx N.V.|X4 Pharma (XFOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|inmunebio.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BRNS|KZR (Kezar Life Sciences Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SABS (SAB Biotherapeutics, Inc)|EV/EBITDA Multiple Akari Therapeutics, Plc AKTX|ENLV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation QTTB (Q32 Bio Inc.)|GeoVax (GOVX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Edesa Biotech Inc|IBIO (iBio Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Carisma Tx|Enterprise Value to EBITDA Ratio XTLB (XTL Biopharmaceuticals)|BOLT (boltbio.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple HCWB (HCW Biologics)|Total Company Value to Operating Income Before Depreciation Ratio Aptevo Therapeutics, Inc. (APVO)|AIM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aditxt (ADTX) - Enterprise Value to EBITDA Ratio|GRI Bio, Inc. (GRI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio xortx.com|Enterprise Value to EBITDA Ratio HIND|EV/EBITDA Multiple Revelation Biosciences Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Indaptus (INDP)|BiondVax Pharmaceuticals - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple CALI (CalciMedica)|Affimed NV (AFMD) - Company Value to EBITDA|Allakos Therapeutics - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio HOOKIPA Pharma Inc. HOOK|IGMS (igmbio.com) - Enterprise Value to EBITDA Ratio|OCEA: Enterprise Value to Operating Income Before Depreciation Ratio|TCBP (TC Biopharm) - EV/EBITDA Multiple|Company Value to EBITDA thirdharmonicbio.com THRD
